256944-03-3

Upstream product

• 103545-98-8 phenyl-2-isopropyl-5-oxovaleronitrile 
• 5558-29-2 3-methyl-2-phenyl-butyronitrile 
• 256943-67-6 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-4-(2-hydroxyethyl)piperazine 
• 140-29-4 phenylacetonitrile 

Downstream Products

• 255847-61-1 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-4-[2-(6-quinolyloxy)ethyl]piperazine 
• 255847-72-4 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-4-[2-(5-quinolyloxy)ethyl]piperazine 
• 255847-76-8 1-[(4-cyano-5-methyl-4-phenyl)hexyl]-4-[2-(4-quinazolinyloxy)ethyl]piperazine 

Relevant academic research and scientific papers

Discovery of novel neuronal voltage-dependent calcium channel blockers based on emopamil left hand as a bioactive template

A series of novel neuronal voltage-dependent calcium channel (VDCC) blockers, with inhibitory activity at low micromolar and moderate solubility in water, was discovered by constructing and screening a focused library based on emopamil (1) left hand (ELH)

N,N-SUBSTITUTED CYCLIC AMINE DERIVATIVES

N,N-substituted cyclic amine derivatives represented by general formula (VIII) or pharmacologically acceptable salts thereof: wherein A represents aryl, etc.; E represents -CO- or -CHOH-; G represents oxygen, etc.; J represents optionally substituted aryl; R1 represents lower alkyl, etc.; Alk represents linear or branched lower alkylene; n, v, w, x and y independently represent each 0 or 1; and p represents 2 or 3. These compounds or salts thereof are efficacious in treating diseases against which calcium antagonism is efficacious. These diseases include cerebrovascular disorder at the acute stage, cerebral stroke, cerebral infarction, head injury, cerebral nerve cell death, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, brain circulatory disturbance, brain function disturbance, pain, convulsion, schizophrenia, hemicrania, epilepsy, circular psychosis, nerve degeneration diseases, brain ischemia, AIDS, complex dementia, edema, anxiety and diabetic nephropathy.